Practice Essentials

Posttraumatic stress disorder (PTSD) is a syndrome resulting from exposure to real or threatened serious
injury or sexual assault. The signs and symptoms of PTSD appear to arise from complex interactions of
psychological and neurobiological factors. Studies have found alterations in the amygdala, prefrontal
cortex, hippocampus, and anterior cingulate, and corpus collosum as well as altered functioning of the
hypothalamic pituitary axis (HPA).

Signs and symptoms

Symptoms of posttraumatic stress disorder (PTSD) include the following:

 Persistently reexperiencing of the event: intrusive thoughts related tto the traumatic event,
nightmares or distressing dreams, persistent or recurrent involuntary memories, dissociation
(including flashbacks) and intense, negative emotional or physiological reaction on exposure to
reminders (traumatic triggers)

 Avoidance of traumatic triggers or of thinking/talking about the experience

 Negative alterations in cognition and mood: inability to recall important aspects of the trauma;
persistent negative beliefs and expectations about oneself, others, and the world; inappropriate
blaming of oneself for the trauma; exaggerated negative beliefs about the consequences of the
trauma; persistent negative emotional state (sadness, horror, guilt); a paucity of positive
emotional experiences; loss of interest or participation in important activities; and detachment
from people.

 Increased arousal or reactivity: irritability, problems with sleep or concentration, increased

startle reaction, increased vigilance for potential danger, self-harming acts, or recklessness

One cannot diagnose PTSD until one month has passed since the traumatic incident. Acute stress
disorder, which has similar symptoms, is diagnosed during the first month.

Diagnosis

Diagnosing PTSD in adults, adolescents, and children older than 6 years of age using the Diagnostic and
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [2] requires a certain type and level of
traumatic event, a combination of required symptoms, and the absence of exclusionary criteria.

A) Causation: The victim was exposed to actual or threatened death, serious injury or sexual violence in
one of four ways:

 Directly experiencing the traumatic event(s)

 Witnessing, in person, the event(s) as it occurred to others

 Learning that the traumatic event(s) occurred to a close family member or friend
  Experiencing repeated or extreme exposure to aversive details of the traumatic event(s); this
does not apply to exposure through media such as television, movies, or pictures

B) The traumatic event is persistently re-experienced:

 nightmares

 intrusive thoughts of the traumatic event

 flashbacks

 marked emotional distress when exposed to traumatic reminders

 strong physiologic reaction when exposed to traumatic reminders

Children may reexperience the event through repetitive play.

C) Avoidance in one of two ways:

 Avoidance of thoughts, feelings, or conversations associated with the event

 Avoidance of people, places, or activities that may trigger recollections of the event

D) Negative alterations in cognition and mood. Two of the following:

 Inability to remember an important aspect of the event(s)

 Persistent and exaggerated negative beliefs about oneself, others, or the world

 Persistent distorted cognitions about the cause or consequences of the event(s)

 Persistent negative emotional state

 Markedly diminished interest or participation in significant activities

 Feelings of detachment or estrangement from others

 Persistent inability to experience positive emotions

E) Hyperarrousal: Two of the following:

 Irritable behavior and angry outbursts

 Reckless or self-destructive behavior

 Hypervigilance

 Exaggerated startle response

 Concentration problems
  Sleep disturbance

F) The duration of symptoms is more than 1 month

G) Disturbance causes clinically significant distress or impairment in functioning

H) The disturbance is not attributable to the physiological effects of a substance or other medical
condition

DSM-5 recognizes a“with dissociative symptom” specifier when the PTSD symptoms are accompanied by
persistent or recurrent depersonalization or derealization.

The specifier “with delayed expression” should be included if the full criteria for PTSD are not met for
more than 6 months following the trauma.

Children may have different reactions to trauma than do adults. Children aged 6–11 years may show
extreme withdrawal, disruptive behavior, and/or an inability to pay attention. Regressive behaviors,
nightmares, sleep problems, irrational fears, irritability, refusal to attend school, outbursts of anger, and
fighting are also common. The child may have somatic complaints with no medical basis. Schoolwork
often suffers. Depression, anxiety, feelings of guilt, and emotional numbing are often present.
Adolescents aged 12–17 years generally have responses similar to those of adults. [26]

For children aged 6 years or younger, typical reactions to trauma can include regressive behavior, a fear
of being separated from a parent, crying, whimpering, screaming, immobility and/or aimless motion,
trembling, frightened facial expressions, and excessive clinging. Children are strongly affected by their
parents' reactions to the traumatic event and their parents’ ability to provide support. [26] Special criteria
for the diagnosis of PTSD in children 6 years of age and under are found in the DSM-5. [2]

Management

Treatment includes the following:

 Psychological First Aid is very important in the immediate aftermath of a traumatic event.
Psychological First Aid includes psychoeducation that the patient's initial symptoms are a normal
reaction to an abnormal event and do not mean the person is weak or going crazy, and that the
symptoms will subside with time. First aid also includes providing for the individual’s basic needs
(shelter, food, and supportive relationships) and reassurance that support will continue. It is
important to avoid making invalidating comments such as: its not that big a deal, why are you so
upset.

 Evidence-based therapies for PTSD include Trauma Focused Cognitive Behavioral Therapy (TF-
CBT) Prolonged Exposure (PE), Cognitive Processing Therapy, and Eye Movement Desensitization
and Reprocessing (EMDR). Psychotherapy is clearly more effective than medication. Certain
medications may be helpful in increasing the effectivenenss of therapy. D-cycloserine, which
enhances memory, may help with extinction learning. Inderal may help to decrease arousal
 during therapy and may make extinction learning more effective. However, inderal also impairs
memory. [80]

 The SSRI and SNRI antidepressants appear to be the most effective psychopharmacological
interventions for the symptoms of PTSD in adults. Their efficacy is adolescents and children is
certainly less and they may not have any efficacy. In addition, they carry Black Box warnings for
suuicidality. Guanfacine and Clonidine can be helpful for agitation. Prazosin is sometimes
helpful decreasing trauma-related nightmares and insomnia. Use of Inderal in the first few
hours may decrease future hyperarrousal symptoms. Use of benzodiazepines ha been shown to
worsen the course of PTSD.

 Playing a visually demanding game such as Tetris shortly after the traumatic event may help to
interfere with consolidation of the memory and may decrease the risk of developing PTSD.

Background

The psychological problems of soldiers in World War II, the Korean War, and the Vietnam War, along
with the severe psychological impact of rape, fostered interest and research in the collection of
symptoms that became known as Posttraumatic stress disorder. PTSD was first included in the
Diagnostic and Statistical Manual of Mental Disorders in 1980 when DSM-III was published. The
diagnostic criteria have undergone significant revisions with DSM-IV and DSM-5.

 Under DSM-III one had to experience an event outside of normal human experience that would
cause symptoms in almost anyone. In time, appreciation that the symptom cluster occurred as a
result of common experiences, such as car accidents, led to a change in the criteria.

 DSM-IV required that the individual respond to the trauma with “intense fear, helplessness, or
horror.” Although the DSM-5 contains these as a possible manifestation of PTSD, the
requirement for them was dropped. DSM-5 also moved PTSD from the "Anxiety Disorders" to a
new category of disorders referred to as "Trauma- and Stressor-Related Disorders."

 Previous criteria focused on the clusters of re-experiencing, avoidance, and hyperarousal. This
has been slightly modified in the DSM-5, which now includes intrusive symptoms (similar to the
older re-experiencing category), avoidance, negative changes to cognitions and emotions, and
altered arousal and reactivity.

 Traumatic events had been limited to life-threatening occurrences such as natural disasters,
personal assaults, war, or severe accidents.The DSM-5 included the possibility of developing
PTSD following sexual violence even if there was no threat of death. For children, a
developmentally inappropriate sexual experience may be considered a traumatic event, even
though it may not have actually involved violence or physical injury.

 The DSM-5 recognizes a new, dissociative subtype of PTSD, with clinical and neurobiological
features that distinguish it from the non-dissociative form. [6] This dissociative subtype is
described as an over-modulation of affect, or a form of emotional dysregulation mediated by
 midline prefrontal inhibition of limbic regions. This subtype may require slight differences in
treatment. [4]

 The DSM-5 now includes differing criteria for diagnosing PTSD in children 6 years of age and
younger. Although the criteria are similar to those used in diagnosing PTSD in older populations,
there are developmentally appropriate alterations. [2]

Etiology

The etiology of PTSD is experiencing a serious threat of physical injury or death, or sexual assault.
Children who suffer repeated child abuse are at risk for complex trauma. Chronic PTSD represents a
failure to recover from the trauma, in part due to inadequate resilience. Considerable effort has been
spent in an attempt to determine which individuals will have prolonged, maladaptive responses to
trauma. Numerous risk factors have been determined. . [2, 81]

Pre-existing factors

Pre-existing factors include the following:

 Gender (increased in women)

 Prior traumatic exposure

 Pre-existing mental illness

 Lower socioeconomic status

 Less education, lower intelligence

 Childhood adversity

Peritraumatic factors

See the list below:

 Severity and nature of trauma

 Interpersonal violence

 Dissociation at the time of the traumatic event

 Increased pulse right after the traumatic event

Posttraumatic factors

See the list below:

 Development of Acute Stress Disorder

  Other stresses such as financial problems

 Subsequent adverse life events

 Lack of social support

Epidemiology

Exposure to traumatic events is common. Among adults in the United States, as many as 50% of women
and 60% of men have experienced a traumatic event. Most of these individuals will not develop
PTSD. PTSD has a lifetime prevalence among adults in the United States of roughly 8% (higher in women
than men) and accounts for considerable disability and morbidity. These rates vary considerably
depending on the specific population being considered. [78]

Prognosis

Prognosis varies based on a number of factors in including resilience, secondary stresses, level of
support, prior traumatic experiences, ongoing injury, severity of the stressor, etc.

The child's resilience is an important factor in prognosis. [81]

Three years after Hurricane Katrina the prevalence of serious emotional disturbance for children in the
area with high exposure (serious economic or housing problems, injury or death of someone close to
them or victimization) was roughly one in three children. [78]

Child abuse and neglect predispose to personality disorders, affective disorders, substance abuse and
medical problems. [82]

Patient Education

Family members of those with PTSD are also impacted by the trauma particularly through the
detachment and irritability of the person with PTSD. Family members may desire to be supportive but
are not clear what conversations to have or how best to show their concern and support. For many
individuals with PTSD, comprehensive treatment includes involvement of the family in some form.

For patient education information, see the Mental Health Center, as well as Post-traumatic Stress
Disorder (PTSD) and Stress.

The following Web sites also provide valuable information for patients and their families: US
Department of Veteran Affairs National Center for PTSD, US Army Office of Behavioral Health,
Afterdeployment.org, National Institute of Mental Health, American Academy of Child and Adolescent
Psychiatry, and Mayo Clinic.
Pathophysiology

In addition to the psychological impact of experiencing a traumatic event, PTSD frequently leads to
changes in the anatomy and neurophysiology of the brain. Reduced size of the hippocampus is probably
both a predisposing factor and a result of trauma. The amygdala, which is involved in processing
emotions and modulating the fear response, seems to be overly reactive in patients with PTSD. The
medial prefrontal cortex (mPFC), which exhibits inhibitory control over the stress response and
emotional reactivity of the amygdala, appears to be smaller and less responsive in individuals with PTSD.
[35, 75, 76, 77, 84]

Alterations in neurohormonal and neurotransmitter functioning have also been found. Individuals with
PTSD tend to have normal to low circulating levels of cortisol despite their ongoing stress and elevated
levels of Corticotropin Releasing Factor (CRF). Cortisol leads to decreased production of CRF. If cortisol is
low then CRF continues to be high and stimulates norepinephrine release by the anterior cinculate
cortex. Individuals with PTSD demonstrate hyperactivity of the sympathetic branch of the autonomic
nervous system, as evidenced by changes in heart rate, blood pressure, skin conductance level, and
other psychophysiological measures. They also have elevated noradrenergic reactivity to
pharmacological challenges. A variety of other neurotransmitter systems, such as the serotonin, GABA,
glutamate, neuropeptide Y, and endogenous opioids, show altered functioning in individuals with PTSD.
[84]

Further insight into the pathophysiology of PTSD may be found in the Dual Representational
Theory. This understanding highlights the presence of two separate systems for memory. Verbally
accessible memory (first recorded in the hippocampus and later in general brain memory storage) is
able to be modified by reflection. This is characteristic of most non-traumatic memories. Situationally
accessible memory, on the other hand, is non-verbal and associated with very strong emotions and the
amygdala. Traumatic memories tend to be stored as situationally accessible memories, which are harder
to process, are readily triggered by associations, and more likely to cause emotional distress when
activated. Individuals may struggle to integrate these traumatic experiences with the rest of their life
narrative thereby resulting in the traumatic memory having a significant impact on their views of the
world and themselves. [71, 72]

Associated Concepts

Complex trauma and disorders of extreme stress not otherwise specified (DESNOS)

In the 1990s, Van Der Kolk and others began promoting the concept of “Complex PTSD.” It is also
referred to as Disorder of Extreme Stress Not Otherwise Specified (DESNOS). DESNOS arises from
severe, protracted abuse, most notably childhood sexual abuse, victims of torture, and living in a war
zone. This type of trauma often leads to the use of primitive defense mechanisms (splitting and
dissociation), which causes significant interpersonal problems and emotional struggles in addition to the
standard symptoms of PTSD. Complex PTSD often leads to poor resilience, increased risk of depressive
and anxiety disorders, and somatization. Numerous situations will trigger these individuals and lead to
very strong adverse emotional reactions. The great majority of individuals who develop Borderline
Personality Disorder or Dissociative Identity Disorder suffered complex trauma during
childhood. Although many clinicians find this to be a useful conceptualization, it does not appear in the
DSM-5. [73, 85]

Betrayal trauma

Freyd and others have developed the concept of betrayal trauma. Betrayal trauma does not fulfill the
diagnostic criteria for PTSD because it does not entail a serious threat of injury or sexual assault.
Nevertheless, betrayal, such as a spouse having an affair or abandonment by a parent can result in most
of the same symptoms that PTSD can cause. [69, 70] Symonds argued that some of the symptoms we
normally attribute to the initial traumatic event are actually the result of the individual feeling betrayed
by those (s)he expected to provide support. Child abuse includes betrayal trauma because parents and
teachers are supposed to protect children, not abuse them.

History

The diagnosis of posttraumatic stress disorder is based on evidence of having experienced a serious
threat of physical injury or a sexual assault. followed by the symptoms of PTSD. Because of the
frequent comorbidities providers should also ask about the following:

 Depressive symptoms

 Anxiety symptoms

 Substance abuse

 Suicidal ideation

 Relationship problems

Physical Examination

Patients may display physiological arousal (e.g., tremor, sweating, agitation) when they are discussing
their trauma. Individuals may also present with physical injuries related to the trauma (e.g., traumatic
amputation from an explosion or bruises in victims of ongoing domestic abuse). Those who have
experienced a head injury should be checked for evidence of neurological impairment.

Autonomic arousal in the immediate aftermath of the traumatic events indicates an increased risk of
PTSD.. [32]

Mental Status Examination

Factors discovered during the mental status examination may help confirm the diagnosis of PTSD. These
may include:

 Behavioral Factors
 o Increased vigilance

o Increased startle response

o Physiological arousal or emotional distress when discussing the trauma

o Inability to engage with providers

 Cognitive Factors

o Amnesia for parts of the traumatic events

o Distorted thoughts of self, others and the world

o Distorted thoughts about the cause or consequences of the trauma

o Problems with concentration

 Emotional Factors

o Decreased range of positive emotions

o Persistent negative emotional states

Complications

Psychiatric and medical comorbidities are common with PTSD. Among individuals with PTSD there are
increased rates of:

 Mood disorders

 Panic and other anxiety disorders

 Substance abuse disorders [27, 28, 58, 62]

 Neurological conditions (e.g., headaches, dementia) [5]

Substance abuse is a particular problem for individuals with PTSD. Studies have found that up to 51.9%
of men with PTSD concomitantly misuse alcohol. In one study, men with PTSD reported an earlier age of
onset of alcohol dependence, greater alcohol use intensity and craving, and more severe legal problems
due to alcohol use. In the same study, PTSD more often preceded alcohol dependence in women than
men and women were more likely to test positive for cocaine upon entering treatment. [27] Use of
analgesic medications (opiate and non-opiate) may be raised among individuals with PTSD. [28]

Diagnostic Considerations

Other diagnoses to consider include the following:

 Acute stress disorder

  Adjustment disorder

 ADHD

 Malingering

 Depression

 Anxiety Disorder

 Obsessive Compulsive Disorder

 Substance Abuse

 Medical problem

 Post-concussion Syndrome

 Psychosis

Differential Diagnoses

 Anxiety Disorders

 Obsessive-Compulsive Disorder

 Schizophrenia

Approach Considerations

Primary care and mental health providers can efficiently screen for PTSD using readily available self-
administered tests. This should become standard of care as one study found that nearly half (48%) of
the patients in general medical practices with PTSD were receiving no mental health treatment. One
primary reason for this lack of treatment was providers not recognizing the diagnosis and
recommending treatment. [34] Mental health providers who do not ask about trauma may also miss the
key role that PTSD plays in their patient’s symptoms.

There are a number of self-report scales that can be used for screening or management [59, 60, 61] :

 Distressing Events Questionnaire (DEQ)

 PTSD Checklist for DSM-5 (PCL-5)

 Screen for Posttraumatic Stress Symptoms (SPTSS)

 Trauma Symptom Checklist - 40 (TSC-40)

 Trauma Symptom Inventory (TSI)

Lab Studies

There are no lab studies that are currently recommended for diagnosing PTSD, but they may be helpful
in assessing for the substance use disorders, which commonly accompany PTSD.

Cortisol levels may be decreased, while norepinephrine and CRF levels may be elevated; however, these
findings are currently used only for research.

Imaging Studies

While there are some consistent anatomical and functional studies in individuals with PTSD such as
small hippocampi, decreased corpus collosum, decreased pre frontal cortex, increased reactivity in the
amygdala, and decreased activity in the prefrontal cortex, these are currently used only for research.

Other Tests

Although increased arousal is not a required criterion for diagnosis, it might be measurable through
studies of autonomic functioning (e.g., heart rate monitoring, electromyography, sweat gland activity).

Increased heart rate shortly after the traumatic event indicates an increased risk of PTSD.

Approach Considerations

Secondary prevention of PTSD

Secondary prevention consists of interventions designed to decrease the rate of PTSD in individuals
exposed to traumatic events.

While no definitive studies exist, it is commonly believed that Psychological First Aid may decrease rates
of PTSD following a natural disaster or mass casualty situation. Psychological First Aid includes emotional
support, decreasing stress by reassuring the victim that shelter, food and access to loved ones is
guaranteed. Helping the person find a tolerable meaning for the trauma, reducing ideas leading to
shame or guilt, avoiding invalidating comments such as it is not that bad, reassuring the victim that their
strong emotional reaction is normal and does not mean they are weak or will forever feel this way can
all be helpful.

Controlled trials have not found that single individual or group debriefings done in the immediate
aftermath of traumas have been successful in preventing the development of PTSD. [88] They also risk
flooding victims. Pressuring a victim to participate can retraumatize them. Group treatment of trauma
victims runs the risk of victims becoming worse as a result of flooding from hearing the stories of other
members. Group treatment for PTSD must have very careful selection of group members to avoid this.
Forcing victims to speak about the event, as has happened through required debriefing sessions, can be
very harmful.
Brief cognitive-behavioral therapy (CBT) started within a few weeks of a traumatic event has been show
to decrease the rate of subsequent PTSD. Brief CBT appears to have the biggest impact in patients who
have the most symptoms. [89]

Attempts to decrease the formation of PTSD through pharmacology continues to be studied. Aggressive
pain control is important to avoid increasing the trauma to the individual. Hydrocortisone has been
shown to be effective. Individuals with low cortisol levels at the time of the trauma are at greater risk for
the development of PTSD. Low cortisol levels lead to increased production of CRF, which increases
norepinephrine release by the anterior cingulate. Some research has shown that propranolol given in
the first hours after the traumatic event leads to reduced hyperarrousal in the future. Trials of
escitalopram, temazepam, and gabapentin have been unsuccessful in preventing PTSD following
trauma. [89] Benzodiazepines appear to be harmful.

High levels of emotional support and help with basic needs for shelter, food, clothing, and economic
issues likely decrease the risk of PTSD.

Trauma-focused CBT and eye movement desensitization and reprocessing (EMDR) have been shown to
be most effective in treating patients with PTSD. [36, 37, 38, 39, 46, 47, 49, 56]

Studies have suggested that even a single CBT session for sleep abnormalities can significantly improve
daytime PTSD symptoms, as can pharmacologic treatments for sleep abnormalities. [41, 42]

In 2013, the World Health Organization (WHO) issued new clinical protocols and guidelines for
addressing the mental health consequences of PTSD, acute stress, and bereavement. The new protocols
allow primary healthcare workers to offer basic psychosocial support to refugees as well as people
exposed to trauma or loss in other situations. Types of support offered may include psychological first
aid, stress management, and helping affected people to identify and strengthen positive coping
methods and social supports. Referral for advanced treatments such as CBT or EMDR should also be
considered. Benzodiazepine use for the reduction of acute traumatic stress symptoms or sleep problems
in the first month after a potentially traumatic event is not recommended. [43, 44]

Treatment of PTSD

Psychotherapy

Trauma-focused psychotherapies appear to be effective treatment for PTSD. A systematic review and
meta-analysis of 55 clinical trials found that evidence-based trauma-focused psychotherapy (TFP)
outperformed medications when looking at pre-/post-treatment symptoms and at 9-month follow-
up. In this meta-analysis, TFP included trauma-focused CBT, prolonged exposure, cognitive processing
therapy, eye movement desensitization and reprocessing (EMDR), and imaginal exposure. [90] There is
limited data supporting more generalized CBT approaches such as stress inoculation training and
relaxation training. [36, 37, 44, 46, 47, 49, 56]

There are ongoing efforts to assess variations of psychotherapy and psychotherapies that target specific
symptoms such as insomnia. A trial study of service members with PTSD caused by the traumatic events
of September 11, 2001, or by Operation Iraqi Freedom, found that self-managed, Internet-based CBT led
to a greater reduction in PTSD symptoms than did Internet-based supportive counseling. [40] Studies
have suggested that even a single CBT session for sleep abnormalities can significantly improve daytime
PTSD symptoms. [41, 42]

Trauma focused cognitive behavioral therapy is effective in treating PTSD in children and
adolescents. There is insufficient evidence, however, to definitively compare one form of psychotherapy
to another. [47] The most recent research says therapy shortens the course of those who will recover but
does not change the long-term course. [79]

Psychopharmacology

Recommendations for pharmacological treatment vary depending on the source. The United Kingdom’s
National Institute for Health and Care Excellence (NICE) and the World Health Organization (WHO) do
not recommend any medications as first-line treatment for PTSD. The American Psychiatric Association
and the US Department of Veterans Affairs and Department of Defense Clinical Practice Guidelines both
recommend antidepressants (particularly SSRIs) as first-line treatment for PTSD. Both organizations also
support the use of prazosin for trauma-related nightmares and insomnia. Benzodiazepine use for the
reduction of acute traumatic stress symptoms or sleep problems after a potentially traumatic event is
not recommended. [43, 44, 88, 92] Although benzodiazepines may be popular with patients and lead to a
transient decrease in anxiety symptoms, research indicates that they not only are not effective, but may
prolong the course of PTSD. [93, 94]

Inpatient care

Inpatient care may be necessary if the patient becomes an acute danger to themselves or others.
Individuals with severe PTSD from childhood abuse may need inpatient care to help learn emotional
regulation and then treat the PTSD.

Medication Summary

While a large number of medications have been tried, few have been shown to have any efficacy. The
SSRIs and SNRIs are generally the first-line medications for adults, but only sertraline and paroxetine
have FDA approval. Their efficacy in children and adolescents is not proven. Moreover, they have
significant side effects. They carry Black Box warnings for suicidal ideation. Benzodiazepines increase
the risk of PTSD developing. [66, 67, 68, 74, 49, 51, 94]

Agitation is best treated with Clonidine and Guanfacine.

Insomnia is a common problem for patients with PTSD. It may be treated though reinforcing sleep
hygiene and CBT. Clonidine and Prazocin may be helpful. Prazosin decreases trauma-related
nightmares. [42, 96] Trazadone may be helpful.

Antipsychotics and anti convulsants have been tried. Studies have not shown benefit worth the sid
effects.
There is a huge placebo effect for medication. You are likely to find benefit with whatever you give, but
it is probably placebo effect.

Selective serotonin reuptake inhibitors

Class Summary

The selective serotonin reuptake inhibitors (SSRIs) work by blocking the reuptake of serotonin. SSRIs
such sertraline (Zoloft) and paroxetine (Paxil) have been FDA approved to treat PTSD as well as other
disorders.

Sertraline (Zoloft)

 View full drug information

Sertraline is an SSRI that is FDA approved for the treatment of PTSD, panic disorder, social anxiety, and
obsessive-compulsive disorder. It may be particularly useful in women who have experienced sexual or
physical assaults.

Paroxetine (Paxil, Pexeva)

 View full drug information

Paroxetine is FDA approved to treat PTSD. It is used to reduce symptom severity of PTSD. It is a potent,
selective inhibitor of neuronal serotonin reuptake. It also has a weak effect on norepinephrine and
dopamine neuronal reuptake. It is also FDA approved for panic disorder, depression, social anxiety
disorder, and obsessive-compulsive disorder.

Fluoxetine (Prozac)

 View full drug information

Fluoxetine selectively inhibits presynaptic serotonin reuptake with minimal or no effect on the reuptake
of norepinephrine or dopamine. SSRIs as fluoxetine have less sedation, cardiovascular, and
anticholinergic effects than the tricyclic antidepressants (TCAs). Studies have shown this drug to be
superior for measures of PTSD severity, disability, and high end-state function.

Beta-blockers

Class Summary

Beta-blockers such as propranolol are useful in controlling some symptoms of PTSD caused by
hyperarousal. A pilot study revealed propranolol is effective for decreasing physiological signs of
hyperarousal for up to 1 week when used shortly after patients with PTSD reexperience their traumatic
event. [50] Ideally, propranolol is to be used within 6 hours of the initial traumatic event, well before a
diagnosis of PTSD is made. Larger randomized, placebo-controlled studies are warranted to confirm
these findings.
Propranolol (Inderal LA, Inderal XL, Hemangeol, Innopran XL)

 View full drug information

Propranolol is a nonselective beta-adrenergic receptor blocking agent. It has been found to relieve
exaggerated startle response, explosiveness, nightmares, and intrusive reexperiencing in some patients
with PTSD. Propranolol has not been FDA approved for these indications.

Alpha-1 Receptor Antagonists

Class Summary

Novel pilot studies in combat veterans suggest alpha-1 antagonists have efficacy on the sleep-associated
symptoms of PTSD. Alpha-1 antagonists have not been FDA approved for this indication.

Prazosin (Minipress)

 View full drug information

Prazosin is an alpha-1 adrenergic blocker that is indicated for hypertension. Studies indicate that a
nighttime dose of prazosin (10-15 mg) decreases nightmares and sleep disturbances in combat veterans
with PTSD and increases normal dreaming patterns. Additional pilot trials have suggested that a
midmorning dose of prazosin also helps to decrease daytime PTSD symptoms in civilian and military
patients. However, larger, randomized, placebo-controlled trials are needed to confirm these results.

Alpha-2 Adrenergic Agonists

Class Summary

Agents in this class may decrease vasomotor tone and heart rate by stimulating alpha2-adrenoreceptors
in the brain stem and activating an inhibitory neuron.

Clonidine (Catapres, Catapres-TTS, Duracion, Kapvay)

 View full drug information

Clonidine is a central alpha-adrenergic agonist that is commonly used as an antihypertensive agent. It

stimulates alpha2-adrenoreceptors in the brain stem and activates an inhibitory neuron, resulting in a
decrease in vasomotor tone and heart rate. Clonidine may have potential effects on the hyperarousal
symptoms of PTSD. It may also help in patients experiencing nightmares.
REFERENCE

1. Risser HJ, Hetzel-Riggin MD, Thomsen CJ, McCanne TR. PTSD as a mediator of sexual
revictimization: the role of reexperiencing, avoidance, and arousal symptoms. J Trauma Stress.
2006 Oct. 19(5):687-98. [Medline].
2. American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders, Fifth Edition. Arlington, VA: 2013.
3. Pollack MH, Hoge EA, Worthington JJ, et al. Eszopiclone for the treatment of posttraumatic
stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J
Clin Psychiatry. 2011 Jul. 72(7):892-7. [Medline].
4. Yaffe K, Vittinghoff E, Lindquist K, Barnes D, Covinsky KE, Neylan T, et al. Posttraumatic stress
disorder and risk of dementia among US veterans. Arch Gen Psychiatry. 2010 Jun. 67(6):608-13.
[Medline]. [Full Text].
5. Krahe B, Scheinberger-Olwig R, Waizenhofer E, Kolpin S. Childhood sexual abuse and
revictimization in adolescence. Child Abuse Negl. 1999 Apr. 23(4):383-94. [Medline].
6. Deykin EY. Posttraumatic Stress Disorder in Childhood and Adolescence: A Review. 1999.
Medscape Mental Health [online]. Available at http://medscape.com.
7. Marshall RD, Pierce D. Implications of recent findings in posttraumatic stress disorder and the
role of pharmacotherapy. Harv Rev Psychiatry. 2000 Jan-Feb. 7(5):247-56. [Medline].
8. Milad MR, Orr SP, Lasko NB, Chang Y, Rauch SL, Pitman RK. Presence and acquired origin of
reduced recall for fear extinction in PTSD: results of a twin study. J Psychiatr Res. 2008 Jun.
42(7):515-20. [Medline]. [Full Text].
9. Johnson H, Thompson A. The development and maintenance of post-traumatic stress disorder
(PTSD) in civilian adult survivors of war trauma and torture: a review. Clin Psychol Rev. 2008 Jan.
28(1):36-47. [Medline].
10. Hoge CW, Auchterlonie JL, Milliken CS. Mental health problems, use of mental health services,
and attrition from military service after returning from deployment to Iraq or Afghanistan.
JAMA. 2006 Mar 1. 295(9):1023-32. [Medline].
11. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and
Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004 Jul 1. 351(1):13-
22. [Medline].
12. Polusny MA, Kehle SM, Nelson NW, Erbes CR, Arbisi PA, Thuras P. Longitudinal effects of mild
traumatic brain injury and posttraumatic stress disorder comorbidity on postdeployment
outcomes in national guard soldiers deployed to Iraq. Arch Gen Psychiatry. 2011 Jan. 68(1):79-
89. [Medline].
13. Harrison, P. Female Vietnam Vets at Higher Risk for Lifetime/Current PTSD. Medscape Medical
News. Available at http://www.medscape.com/viewarticle/852243. October 7, 2015; Accessed:
November 6, 2015.
14. American Psychiatric Association. High Percentage of Youth in the U.S. Report Symptoms of
Posttraumatic Stress and Other Disorders [press release]. Washington, DC: American Psychiatric
Association; Aug 3 2003.
15. Hoge CW, Clark JC, Castro CA. Commentary: women in combat and the risk of post-traumatic
stress disorder and depression. Int J Epidemiol. 2007 Apr. 36(2):327-9. [Medline].
16. Rona RJ, Fear NT, Hull L, Wessely S. Women in novel occupational roles: mental health trends in
the UK Armed Forces. Int J Epidemiol. 2007 Apr. 36(2):319-26. [Medline].
17. National Institute of Mental Health. Helping Children and Adolescents Cope with Violence and
Disasters. NIH Publication No. 01-3518. Bethesda, Md:. National Institute of Mental Health;
2001. [Full Text].
18. Sonne SC, Back SE, Diaz Zuniga C, Randall CL, Brady KT. Gender differences in individuals with
comorbid alcohol dependence and post-traumatic stress disorder. Am J Addict. 2003 Oct-Dec.
12(5):412-23. [Medline].
19. Schwartz AC, Bradley R, Penza KM, Sexton M, Jay D, Haggard PJ, et al. Pain medication use
among patients with posttraumatic stress disorder. Psychosomatics. 2006 Mar-Apr. 47(2):136-
42. [Medline]. [Full Text].
20. Turner JH, Neylan TC, Schiller NB, Li Y, Cohen BE. Objective evidence of myocardial ischemia in
patients with posttraumatic stress disorder. Biol Psychiatry. 2013 Dec 1. 74(11):861-6.
[Medline].
21. Vaccarino V, Bremner JD. Traumatic stress is heartbreaking. Biol Psychiatry. 2013 Dec 1.
74(11):790-2. [Medline].
22. Cassels C. PTSD Independently Linked to Ischemic Heart Disease. Medscape [serial online].
Available at http://www.medscape.com/viewarticle/814375. Accessed: December 2, 2013.
23. Olsson KA, Kenardy JA, De Young AC, Spence SH. Predicting children's post-traumatic stress
symptoms following hospitalization for accidental injury: combining the Child Trauma Screening
Questionnaire and heart rate. J Anxiety Disord. 2008 Dec. 22(8):1447-53. [Medline].
24. Dickie EW, Brunet A, Akerib V, Armony JL. An fMRI investigation of memory encoding in PTSD:
influence of symptom severity. Neuropsychologia. 2008 Apr. 46(5):1522-31. [Medline].
25. Rodriguez BF, Weisberg RB, Pagano ME, Machan JT, Culpepper L, Keller MB. Mental health
treatment received by primary care patients with posttraumatic stress disorder. J Clin
Psychiatry. 2003 Oct. 64(10):1230-6. [Medline].
26. Kasai K, Yamasue H, Gilbertson MW, Shenton ME, Rauch SL, Pitman RK. Evidence for acquired
pregenual anterior cingulate gray matter loss from a twin study of combat-related posttraumatic
stress disorder. Biol Psychiatry. 2008 Mar 15. 63(6):550-6. [Medline]. [Full Text].
27. Hogberg G, Pagani M, Sundin O, Soares J, Aberg-Wistedt A, Tarnell B, et al. Treatment of post-
traumatic stress disorder with eye movement desensitization and reprocessing: outcome is
stable in 35-month follow-up. Psychiatry Res. 2008 May 30. 159(1-2):101-8. [Medline].
28. Ponniah K, Hollon SD. Empirically supported psychological treatments for adult acute stress
disorder and posttraumatic stress disorder: a review. Depress Anxiety. 2009. 26(12):1086-109.
[Medline].
29. Bronson D, Franco K, Budur K. Posttraumatic stress disorder in primary care patients. Compr
Ther. 2007 Winter. 33(4):208-15. [Medline].
30. Nijdam MJ, Gersons BP, Reitsma JB, de Jongh A, Olff M. Brief eclectic psychotherapy v. eye
movement desensitisation and reprocessing therapy for post-traumatic stress disorder:
randomised controlled trial. Br J Psychiatry. 2012 Mar. 200(3):224-31. [Medline].
31. Litz BT, Engel CC, Bryant RA, Papa A. A randomized, controlled proof-of-concept trial of an
Internet-based, therapist-assisted self-management treatment for posttraumatic stress
disorder. Am J Psychiatry. 2007 Nov. 164(11):1676-83. [Medline].
32. Germain A, Shear MK, Hall M, Buysse DJ. Effects of a brief behavioral treatment for PTSD-related
sleep disturbances: a pilot study. Behav Res Ther. 2007 Mar. 45(3):627-32. [Medline].
33. Raskind MA, Peskind ER, Hoff DJ, Hart KL, Holmes HA, Warren D, et al. A parallel group placebo
controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans
with post-traumatic stress disorder. Biol Psychiatry. 2007 Apr 15. 61(8):928-34. [Medline].
34. Brooks M. New WHO Guideline on Mental Health Care After Trauma. Medscape Medical News.
Available at http://www.medscape.com/viewarticle/809185. Accessed: August 14, 2013.
35. Tol WA, Barbui C, van Ommeren M. Management of acute stress, PTSD, and bereavement: WHO
recommendations. JAMA. 2013 Aug 7. 310(5):477-8. [Medline].
36. Lambert MT. Aripiprazole in the management of post-traumatic stress disorder symptoms in
returning Global War on Terrorism veterans. Int Clin Psychopharmacol. 2006 May. 21(3):185-7.
[Medline].
37. Harrison P. Evidence Supports Psychological Therapies for PTSD Kids. Medscape Medical News.
December 11, 2012. [Full Text].
38. Gillies D, Taylor F, Gray C, O'Brien L, D'Abrew N. Psychological therapies for the treatment of
post-traumatic stress disorder in children and adolescents. Cochrane Database Syst Rev. 2012
Dec 12. 12:CD006726. [Medline].
39. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in post-traumatic
stress disorder. Randomised, double-blind study. Br J Psychiatry. 1999 Jul. 175:17-22. [Medline].
40. Davis LL, Frazier EC, Williford RB, Newell JM. Long-term pharmacotherapy for post-traumatic
stress disorder. CNS Drugs. 2006. 20(6):465-76. [Medline].
41. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval
propranolol on psychophysiologic responding during subsequent script-driven traumatic
imagery in post-traumatic stress disorder. J Psychiatr Res. 2008 May. 42(6):503-6. [Medline].
42. Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Johnes, KM, et al. Adjunctive risperidone
treatment for antidepressant-resistant symptoms of chronic military service-related PTSD.
JAMA. Aug 2011. 306(5):461-568.
43. Bandelow B. Defining response and remission in anxiety disorders: toward an integrated
approach. CNS Spectr. 2006 Oct. 11(10 Suppl 12):21-8. [Medline].
44. Bisson JI, Ehlers A, Matthews R, Pilling S, Richards D, Turner S. Psychological treatments for
chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br J Psychiatry.
2007 Feb. 190:97-104. [Medline].
45. Bremner JD. Neuroimaging in posttraumatic stress disorder and other stress-related disorders.
Neuroimaging Clin N Am. 2007 Nov. 17(4):523-38, ix. [Medline]. [Full Text].
46. Brooks M. Heavy drinking, PTSD in college students linked. Medscape Medical News. January 23,
2014. [Full Text].
47. Connor KM, Davidson JR. Further psychometric assessment of the TOP-8: a brief interview-
based measure of PTSD. Depress Anxiety. 1999. 9(3):135-7. [Medline].
48. Hamilton A. Diagnosis and rating of anxiety. Special Publication: Br J Psychiatry; 1969. 3:76-79.
49. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol.
1967 Dec. 6(4):278-96. [Medline].
50. Read JP, Wardell JD, Colder CR. Reciprocal associations between PTSD symptoms and alcohol
involvement in college: a three-year trait-state-error analysis. J Abnorm Psychol. 2013 Nov.
122(4):984-97. [Medline].
51. Zatzick D, Jurkovich G, Rivara FP, Russo J, Wagner A, Wang J, et al. A randomized stepped care
intervention trial targeting posttraumatic stress disorder for surgically hospitalized injury
survivors. Ann Surg. 2013 Mar. 257(3):390-9. [Medline]. [Full Text].
52. Bisson, J. Post Traumatic Stress Disorder. Occupational Medicine. 2007. 57 Issue 6:399-403.
53. Matthew J. Friedman MD PhD. Handbook of PTSD. 2. Guilford; 2014.
54. Hoskins, M., Pearce, J., Bethell, A., et al. Pharmacotherapy for post-traumatic stress disorder:
Systematic review and meta-analysis. The. British Journal of Psychiatry : The Journal of Mental
Science,. 2015. 206 (2):93-100.
55. Freyd J & P Birrell. Blind to Betrayal. Hoboken: Wiley.; 2013.
56. Freyd JJ, Klest B, Allard CB. Betrayal trauma: relationship to physical health, psychological
distress, and a written disclosure intervention. J Trauma Dissociation. 2005. 6(3):.:83-104.
57. Brewin CR, Dalgleish T and Joseph S. A dual representation theory of post-traumatic stress
disorder. Psychological Review. 1996. 103:670-686.
58. Brewin, Chris; Holmes, Emily. Psychological theories of posttraumatic stress disorder. Clinical
Psychology Review. 2003. 23:339–376.
59. Roth, S.; Newman, E.; Pelcovitz, D.; Van Der Kolk, B.; Mandel, F. S. Complex PTSD in victims
exposed to sexual and physical abuse: Results from the DSM-IV Field Trial for Posttraumatic
Stress Disorder". Journal of traumatic stress. Journal of traumatic stress. 1997. 10 (4):539–55.
60. Haagen, JF; Smid, GE; Knipscheer, JW; Kleber, RJ. "The efficacy of recommended treatments for
veterans with PTSD: A metaregression analysis.". Clinical Psychology Review. 2015. 40:184–94.
61. LISA M. SHIN,SCOTT L. RAUCH,ROGER K. PITMAN. Amygdala, Medial Prefrontal Cortex, and
Hippocampal Function in PTSD. Annals of the NY Academy of Sciences. 2006.
62. Giacomo Ronzoni, Alberto del Arco1, Francisco Mora, Gregorio Segovia. nhanced noradrenergic
activity in the amygdala contributes to hyperarousal in an animal model of PTSD.
Psychoneuroendocrinology. 2016. 70:1-9.
63. Bremner JD, Elzinga B, Schmahl C, & Vermetten E. Structural and functional plasticity of the
human brain in posttraumatic stress disorder. . Progress in brain research. 2008. 167:171-86.
64. McLaughlin, K, Fairbank, J, Gruber, M. Trends in Serious Emotional Disturbance among Youths
Exposed to Hurricane Katrina. J of the Am Academy of Child Adolesc Psychiatry. 2010.
49(10):990-1000.
65. Shalev AY, Ankri Y, Gilad M,. Long-Term Outcome of Early Interventions to Prevent
Posttraumatic Stress Disorder. J Clin Psychiatry. 2016. 77(5):580-587.
66. Rothbaum, B. O., Price, M., Jovanovic, T., et al. A randomized, double-blind evaluation of d-
cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic
 stress disorder in Iraq and Afghanistan War Veterans. American Journal of Psychiatry, 171, 640-
648. American Journal of Psychiatry. 2014. 171:640-648.
67. Goldstein S & Brooks R. Handbook of Resilience in Children. Springer.; 2013.
68. Carr CP1, Martins CM, Stingel AM, Lemgruber VB, Juruena MF. The role of early life stress in
adult psychiatric disorders: a systematic review according to childhood trauma subtypes. J Nerv
Ment Dis. 2013. 201(12):1007-20.